Why We Should Treat COVID-19 Long Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes Are Likely COVID Antigen-Specific

The document proposes a potential explanation for the disappointing results of Convalescent Plasma Therapy (CPT) in active COVID-19 infections, suggesting a conflict between beneficial viral resistance-promoting hyper-immune antibodies and undesirable convalescent exosomes that suppress cellular immune responses. The authors postulate that the high incidence of Long Haulers post-COVID patients is due to immune reactivity to antigen remnants of the virus, not residual infection. They propose that CPT, with its content of potential broadly COVID antigen-specific suppressive exosomes, could be an effective treatment for COVID-19 Long Hauler Syndromes, potentially more so than vaccines, as the diverse antigen-specific extracellular vesicles in the convalescent plasma could inhibit multiple COVID antigen-specific responses, not just to the spike protein of the virus.